ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1865

Internet-based Enrollment for Myositis Studies Utilizing Patient Self-reported Diagnostic Criteria

Raisa Lomanto Silva1, Silvia Martinez Laverde1, Siamak Moghadam-Kia1, Nicole Neiman2, Dana Ascherman3, Chester Oddis3 and Rohit Aggarwal4, 1University of Pittsburgh Medical Center, Pittsburgh, PA, 2Division of Rheumatology and Clinical Immunology, Department of Medicine, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh, PA, 4Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2022

Keywords: dermatomyositis, Diagnostic criteria, Myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Recruitment is a major challenge in myositis clinical studies, which is hindered by the rarity and heterogeneity of the disease. Internet-based clinical studies using telemedicine, mobile apps, and wearable devices are a viable solution for enrolling potential subjects. However, establishing criteria to verify the reliability of a patient’s self-reported diagnosis of myositis is essential to improve the feasibility and validity of internet-based recruitment. Our aim was to develop a practical and valid criteria for patient-reported diagnosis of myositis for future internet-based studies.

Methods: The study design was prospective and observational with remote recruitment from anywhere in the US. Myositis patients self-recruited using either a mobile app or the study website. Each patient provided their physician-reported diagnosis (dermatomyositis [DM], polymyositis [PM], necrotizing myopathy [NM]) and self-reported relevant disease diagnostic criteria (DM rash, proximal muscle weakness, muscle/skin biopsy consistent with myositis, EMG consistent with myopathy, creatine kinase [CK] elevation, and/or positive myositis autoantibodies [MAAb]). This was followed by a myositis expert (MD) review of medical records to evaluate the accuracy of diagnosis and disease criteria. We evaluated each of these criterion individually and in combination, to determine optimal sensitivity (SN), positive predictive value (PPV), and percentage agreement with kappa statistics for MD confirmed diagnosis.

Results: A total of 121 remotely-screened patients underwent a review of their medical records by an MD. Patients were predominantly female (n=87, 72%) and white (n=103, 85%), with a mean age of 56.1 (SD 13.5). Of the participants, 65 (53%) had a diagnosis of DM, 49 of PM (40%), and 7 of NM (5.7%). Proximal muscle weakness (n=107, 88%) was the most common criterion reported by patients, followed by CK elevation (n=102, 84%), and positive biopsy (n=79, 65%). EMG, DM rash, and MAAb positivity were reported by 60% (n=73), 56% (n=68), and 37% (n=45) of patients, respectively. The individual criteria of DM rash, weakness, EMG, and CK all had ≥94% SN for IIM diagnosis, with a PPV ranging from 89% for EMG to >97% for rash, weakness, and CK elevation. DM rash and weakness had the best agreement (99% and 96.7% respectively) with MD review. In a combined analysis for IIM diagnosis, weakness and CK elevation had 93% SN and 94.6% PPV. For diagnosis of DM, the combination of DM rash and weakness had 95.3% SN and 95% PPV, resulting in 94% agreement with MD diagnosis. For PM/NM, the combinations of proximal muscle weakness and CK elevation or diagnostic EMG had >94% SN and >94% PPV, with 92.8% and 96.4% agreement respectively.

Conclusion: Patient self-reported myositis diagnostic criteria had high SN, PPV, and agreement with exception of MAAb positivity. In this large national study, patients’ self-report of physician-diagnosed myositis along with self-reported clinical features had excellent sensitivity for the identification of myositis and its subtypes. These criteria can guide the recruitment of subjects for future internet-based studies.

Supporting image 1

Table 1. Disease criteria for IIM and its’ sensitivity, PPV, percentage agreement and, Kappa

Supporting image 2

Table 2. Combination of disease criteria and its’ sensitivity, PPV, percentage agreement, and Kappa for IIM, DM, and PM/NM


Disclosures: R. Lomanto Silva, None; S. Martinez Laverde, None; S. Moghadam-Kia, None; N. Neiman, None; D. Ascherman, None; C. Oddis, None; R. Aggarwal, Mallinckrodt, Bristol Myers Squibb, EMD Serono, Pfizer, Octapharma, CSL Behring, Q32, Kezar, AstraZeneca, Alexion, Argenx, Boehringer Ingelheim, Corbus, Janssen, Kyverna, Roivant, AbbVie, Jubilant, Orphazyme, Genentech.

To cite this abstract in AMA style:

Lomanto Silva R, Martinez Laverde S, Moghadam-Kia S, Neiman N, Ascherman D, Oddis C, Aggarwal R. Internet-based Enrollment for Myositis Studies Utilizing Patient Self-reported Diagnostic Criteria [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/internet-based-enrollment-for-myositis-studies-utilizing-patient-self-reported-diagnostic-criteria/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/internet-based-enrollment-for-myositis-studies-utilizing-patient-self-reported-diagnostic-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology